Moreover, according to the analysis of peritoneal fluid samples from 258 MA patients in a phase II/III study (NCT00836654), catumaxomab therapy can significantly promote the activation of peritoneal T cells and eliminate EpCAM+ tumor cells in a manner associated with the release of proinflammatory Th1 cytokines 123. The gene discussed is EPCAM; the disease is microtia.